Olezarsen is it investigational agent- acetylgalactoseamine conjugated, anti-sense oligonucleotide targeting APOC3 and mRNA for a genetically validated target for triglyceride lowering.

In patients with predominantly moderate hypertriglyceridemia at elevated, cardiovascular risk, Olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major concerns for safety.


Leave a Reply

Your email address will not be published. Required fields are marked *